The heterogeneity of schizophrenia in disease states

Schizophrenia Research
Penny E MohrPeter J Neumann

Abstract

Some of the contents of this paper have been previously presented at the 16th Annual Meeting of the International Society for Technology Assessment in Health Care June 20, 2000 in the Hague, Netherlands and at the 21st Annual Meeting of the Society for Medical Decision Making as a poster on October 3, 1999 in Reno, NV. Studies of schizophrenia treatment often oversimplify the array of health outcomes among patients. Our objective was to derive a set of disease states for schizophrenia using the Positive and Negative Symptom Assessment Scale (PANSS) that captured the heterogeneity of symptom responses. Using data from a 1-year clinical trial that collected PANSS scores and costs on schizophrenic patients (N=663), we conducted a k-means cluster analyses on PANSS scores for items in five factor domains. Results of the cluster analysis were compared with a conceptual framework of disease states developed by an expert panel. Final disease states were defined by combining our conceptual framework with the empirical results. We tested its utility by examining the influence of disease state on treatment costs and prognosis. Analyses led to an eight-state framework with varying levels of positive, negative, and cognitive impairment. The...Continue Reading

References

Sep 1, 1992·The British Journal of Psychiatry : the Journal of Mental Science·K W Brown, T White
Sep 1, 1992·The British Journal of Psychiatry : the Journal of Mental Science·V PeraltaM J Cuesta
Jan 1, 1991·Comprehensive Psychiatry·T Kitamura, R Suga
Jan 1, 1987·Psychopathology·H A WhitefordJ G Csernansky
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Aug 1, 1987·The British Journal of Psychiatry : the Journal of Mental Science·P F Liddle
Jan 1, 1985·Schizophrenia Bulletin·R M BilderA K Pandurangi
Feb 1, 1995·Schizophrenia Research·J P LindenmayerR B Hyman
Jan 1, 1994·Comprehensive Psychiatry·R M Norman, A K Malla
Jan 1, 1996·The British Journal of Psychiatry : the Journal of Mental Science·K W SaxS L McElroy
Aug 1, 1997·Journal of Clinical Psychopharmacology·G Chouinard, P S Albright
Jan 28, 1998·Clinical Therapeutics·C Langley-Hawthorne
Jan 1, 1995·Journal of Mental Health Administration·G R BondD M Fekete
Jun 27, 2000·Journal of Psychiatric Research·T T LeeL A Lenert

❮ Previous
Next ❯

Citations

Oct 1, 2011·Psychometrika·Guan-Hua HuangChung-Chu Hsu
Oct 14, 2008·Schizophrenia Bulletin·Stephen Z Levine, J Rabinowitz
Sep 22, 2011·ClinicoEconomics and Outcomes Research : CEOR·Xiaomei PengJohn M Kane
Nov 30, 2010·Current Medical Research and Opinion·Haya Ascher-SvanumJohn M Kane
Aug 13, 2015·Journal of Autism and Developmental Disorders·Jennifer H Foss-FeigJulie Wolf
Jun 20, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Richard S E KeefeDana C Hilt
Jan 24, 2015·Psychiatry Research·Ariana AndersonRobert M Bilder
Sep 13, 2005·Health and Quality of Life Outcomes·Leslie A LenertChristine Elnitsky
Mar 23, 2013·Clinical Schizophrenia & Related Psychoses·Anatoly KreininMichael Menuchin
Jan 20, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·Bertalan NémethBalázs Nagy
Oct 26, 2018·Journal of Psychopharmacology·Jayashri KulkarniCaroline Gurvich
Sep 16, 2005·Journal of Magnetic Resonance Imaging : JMRI·Vivek SehgalJürgen R Reichenbach
Oct 1, 2005·Journal of Sports Sciences·Magni MohrJens Bangsbo
Oct 31, 2017·Journal of Market Access & Health Policy·A MillierM Toumi
Sep 4, 2007·The British Journal of Psychiatry : the Journal of Mental Science·R A Rosenheck
Feb 10, 2019·European Psychiatry : the Journal of the Association of European Psychiatrists·Wolfgang FleischhackerGyörgy Németh
Oct 20, 2006·Journal of Clinical and Experimental Neuropsychology·Ralf PukropJoachim Klosterkötter
Oct 13, 2019·Brain and Behavior·Yu FangDonghong Cui
Dec 22, 2020·Journal of the International Neuropsychological Society : JINS·Caitlin O B YollandSusan L Rossell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here